• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

FDA OKs First Drug-Eluting Stents for Use in MI

Article

Two drug-eluting stents from Boston Scientific have become the first to be approved by the FDA for treating patients with acute myocardial infarction (AMI), the company announced.

The paclitaxel-eluting Ion and Taxus Liberté stents gained approval for AMI primarily on the strength of the evidence from the HORIZONS-AMI trial.

HORIZONS-AMI randomized 3,006 patients to bare-metal or Taxus stents. At three years, there were no significant differences in safety, including all-cause death, reinfarction, stent thrombosis, or stroke.

Read the full story: http://hcp.lv/yWMJQg

Source: MedPage Today

Related Videos
Beau Raymond, MD
Judith Alberto, MHA, RPh, BCOP, director of clinical initiatives, Community Oncology Alliance
Yuqian Liu, PharmD
Jenny Craven, PharmaD, BCPS
Kimberly Westrich, MA
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Sarah Bajorek, PhD, BCACP, MBA.
Pat Van Burkleo
Video 11 - "Social Burden and Goals of Therapy for Patients with Bronchiectasis"
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.